- Home
- SNT vs ENTX Comparison
SNT vs ENTX Comparison
Compare SNT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- ENTX
- Stock Information
- Founded
- SNT 1965
- ENTX 2010
- Country
- SNT Canada
- ENTX Israel
- Employees
- SNT N/A
- ENTX N/A
- Industry
- SNT Telecommunications Equipment
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNT Telecommunications
- ENTX Health Care
- Exchange
- SNT Nasdaq
- ENTX Nasdaq
- Market Cap
- SNT 95.2M
- ENTX 104.0M
- IPO Year
- SNT 1993
- ENTX 2018
- Fundamental
- Price
- SNT $3.96
- ENTX $1.86
- Analyst Decision
- SNT
- ENTX Strong Buy
- Analyst Count
- SNT 0
- ENTX 1
- Target Price
- SNT N/A
- ENTX $10.00
- AVG Volume (30 Days)
- SNT 80.6K
- ENTX 42.2K
- Earning Date
- SNT 05-27-2025
- ENTX 08-08-2025
- Dividend Yield
- SNT N/A
- ENTX N/A
- EPS Growth
- SNT N/A
- ENTX N/A
- EPS
- SNT 0.18
- ENTX N/A
- Revenue
- SNT $36,690,000.00
- ENTX $223,000.00
- Revenue This Year
- SNT N/A
- ENTX N/A
- Revenue Next Year
- SNT N/A
- ENTX N/A
- P/E Ratio
- SNT $22.00
- ENTX N/A
- Revenue Growth
- SNT 8.36
- ENTX N/A
- 52 Week Low
- SNT $1.34
- ENTX $1.41
- 52 Week High
- SNT $4.29
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- SNT 58.27
- ENTX 40.25
- Support Level
- SNT $3.65
- ENTX $1.87
- Resistance Level
- SNT $3.95
- ENTX $2.28
- Average True Range (ATR)
- SNT 0.25
- ENTX 0.18
- MACD
- SNT -0.02
- ENTX 0.00
- Stochastic Oscillator
- SNT 48.44
- ENTX 28.81
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.